title: Low rather than high dose lipopolysaccharide 'priming' of muscle provides an animal model of persistent elevated mechanical sensitivity for the study of chronic pain.
abstract: Experimental animal pain models involving peripheral nerve lesions have expanded the understanding of the pathological changes caused by nerve damage. However models for the pathogenesis of chronic pain patients lacking obvious nerve injuries have not been developed to the same extent. Guided by clinical observations, we focused on the initiating noxious event, the context when applying nociceptive stimulation targeting long-lasting pain elicited by muscle insult. The administration of a nociceptive agent (6% hypertonic saline: HS; 5-time repeated-injection: HS5) after pretreatment with an immuno-inflammatory agent (lipopolysaccharide: LPS, 2 μg/kg) into one gastrocnemius muscle produced markedly long-persisting biphasic sustained mechanical hypersensitivity on the plantar surface of both hindpaws. In the acute phase, the blockade of afferent inputs from the injected-site was effective in returning the contralateral enhanced-responses to baseline levels. In contrast, similar blockade during the chronic phase did not affect the contralateral enhanced-responses, indicating that the hypersensitivity in the two phases was probably induced by different mechanisms. However, increasing the dose of LPS (20 μg/kg) before applying HS5 eliminated the development of mechanical hypersensitivity in the chronic phase, while the hypersensitivity in the acute phase was significantly more severe than with low-dose LPS-pretreatment. In this model, the development of hypersensitivity could be modulated by manipulating LPS-doses prior to noxious stimulation. This novel chronic pain model based on a preceding 'priming' myalgic stimulus provides an intriguing means for studying the pathogenesis of chronic pain.
authors.affiliation: Department of Algesiology, Aichi Medical University, Nagakute, Aichi 480-1195, Japan. yyama@aichi-med-u.ac.jp
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Yamaguchi
authors.forename: Tatsuyuki
authors.initials: T
authors.lastname: Hashimoto
authors.forename: Hiroki
authors.initials: H
authors.lastname: Sakurai
authors.forename: Takahiko
authors.initials: T
authors.lastname: Yoshimoto
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Ohmichi
authors.forename: Atsuko
authors.initials: A
authors.lastname: Morimoto
authors.forename: Kohei
authors.initials: K
authors.lastname: Harimoto
authors.forename: Mika
authors.initials: M
authors.lastname: Ohmichi
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Eguchi
authors.forename: Takao
authors.initials: T
authors.lastname: Kumazawa
mesh_terms: D000818:Animals; D059350:Chronic Pain / Q000139:chemically induced* / Q000503:physiopathology; D004195:Disease Models, Animal; D006930:Hyperalgesia / Q000139:chemically induced / Q000503:physiopathology*; D007273:Injections, Intramuscular; D008070:Lipopolysaccharides / Q000008:administration & dosage*; D008297:Male; D018482:Muscle, Skeletal / Q000503:physiopathology*; D009619:Nociceptors / Q000502:physiology*; D010147:Pain Measurement; D010812:Physical Stimulation; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D008070:Lipopolysaccharides